This article is more than 5 years old. Information may no longer be current.

Nine important updates in lung cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HemOnc Today presents nine updates in lung cancer that may affect your practice and how you treat your patients.

• Men who reported long-term, high-dose supplementation with vitamins B6 or B12 appeared two to four times more likely than nonusers to develop lung cancer. Male smokers demonstrated the greatest risk. Read more.
• An updated ASCO clinical practice guideline clarifies the appropriate use of immunotherapy and provides new recommendations on the use of targeted therapy for patients with stage IV non-small cell lung cancer. Read more.
• Blood assays identified EGFR mutations in patients with advanced NSCLC with insufficient tumor biopsies. Read more.
• Biocept Inc. and University of Texas Southwestern Medical Center entered a clinical study agreement to evaluate the clinical utility of Biocept’s Target Selector platform for patients with ALK-positive NSCLC. Read more.
• Nearly 3% of patients with advanced lung adenocarcinoma tested positive for the HER-2 gene, the common driver mutation for breast cancer. Thus, HER-2-targeted therapies should be investigated for this patient population. Read more.
• The FDA granted orphan drug designation to tesevatinib (Kadmon Holdings) — an oral tyrosine kinase inhibitor — for the treatment of EGFR-positive NSCLC. Read more.
• Patients with lung cancer appeared more than four times as likely to commit suicide as individuals in the general population. Further, a lung cancer diagnosis increased suicide risk far more than other cancer types. Read more.
• The FDA granted priority review to alectinib (Alecensa, Genentech/Roche) — a kinase inhibitor — for the first-line treatment of patients with ALK-positive, locally advanced or metastatic NSCLC. Read more.
• Peter G. Shields, MD, from The Ohio State University Comprehensive Cancer Center, conducted a weight-of-evidence review to examine why rates of lung adenocarcinomas increased unexpectedly relative to those for other lung cancer subtypes. HemOnc Today spoke with Shields about the weight-of-evidence review, the implications of the findings and why the FDA should consider banning cigarette filter ventilation holes. Read more.